In line with the broader negative trend in overall M&A investment worldwide, the global M&A activity in the life sciences industry experienced a slowdown in 2022: M&A activity declined significantly in both the number and value of deals compared to the previous year.
However, there is hope that 2023 will be a more active year for life sciences deals. Rapidly changing market conditions and improving economic conditions could lead to an increase in dealmaking activity.
Read our Life Sciences M&A Report for more information and statistics on the latest M&A activity in the biotechnology and digital health sectors. The report is published on a quarterly basis by Venture Valuation and is based on data taken from Biotechgate.